Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most statements about thyroid C-cell tumor risk and the MTC/MEN 2 contraindication align with the provided label sections; however, several claims are not supportable or are mismatched to the provided label excerpts (which focus specifically on thyroid C-cell tumor risk/contraindication).
Category Scores
Accurate Statements
Ozempic can cause thyroid C-cell tumors.
Warnings and Precautions (5.1): In mice and rats, semaglutide caused dose-dependent and treatment-duration-dependent increase in thyroid C-cell tumors.
Ozempic can cause thyroid C-cell tumors.
Patient Counseling (17): informs patients that semaglutide causes thyroid C-cell tumors in rodents.
The clinical significance of the animal study finding regarding thyroid C-cell tumors with Ozempic is still unclear.
Warnings and Precautions (5.1) and Nonclinical/Patient Counseling: human relevance of rodent thyroid C-cell tumors has not been determined/unknown.
Animal studies have suggested a higher risk of thyroid C-cell tumors with Ozempic.
Warnings and Precautions (5.1) and Nonclinical Toxicology (13.1): semaglutide caused thyroid C-cell tumors in mice and rats.
The text states that the findings of higher risk of thyroid C-cell tumors in animal studies have raised concerns about the long-term safety of Ozempic.
Warnings and Precautions (5.1): includes rodent tumor findings and explicitly states uncertainty of human relevance; note: the label does not use the exact phrase 'raised concerns' but the concept of uncertainty is aligned.
Unsupported Statements
The text states that a study (JAMA Internal Medicine, 2020) reported a higher risk of thyroid C-cell tumors with Ozempic in animal studies.
No JAMA Internal Medicine (2020) or comparative study citation is present in the provided label excerpts. The label excerpt supports that rodent thyroid C-cell tumors occurred, but does not attribute them to that specific publication.
Patients should be monitored closely for signs of thyroid C-cell tumors.
The label excerpt provides counseling to report symptoms of thyroid tumors and discusses that routine monitoring of calcitonin or using thyroid ultrasound is of uncertain value; it does not specifically recommend 'monitoring closely' for signs.
Contradictions
Important Omissions
For this thyroid C-cell tumor topic, the label states routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection in patients treated with OZEMPIC.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Thyroid C-cell tumor risk and the MTC/MEN 2 contraindication are addressed correctly in supporting excerpts. However, the recommendation to 'monitor closely' is not directly supported by the provided label wording, and it could imply a monitoring approach beyond what the excerpt specifies (which instead notes uncertain value of routine calcitonin/ultrasound).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several thyroid-related claims are unsupported by the provided label excerpts (specific JAMA study citation; directive to monitor closely for signs).
Suggested Improvement
Use label-consistent language: cite that rodent thyroid C-cell tumors occurred and human relevance is unknown; reference the specific contraindication (personal/family history of MTC or MEN 2); frame patient counseling as reporting symptoms (e.g., neck mass, hoarseness, dysphagia, dyspnea) and avoid implying routine 'close monitoring' beyond the label excerpt that states calcitonin/ultrasound monitoring value is uncertain.